Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 0.35 |
| ▸ | DHPS | P49366 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27264858 | 0.84 | HPGD (0.36) | HAO1EPAS1 | |
| SCHEMBL31626038 | 0.84 | HPGD (0.36) | HAO1EPAS1 | |
| SCHEMBL29336749 | 0.83 | F10 (0.44) | — | |
| SCHEMBL29337679 | 0.82 | BRD4 (0.44) | JAK2JAK1JAK3BRD4DHPS | |
| SCHEMBL30217170 | 0.82 | BRD4 (0.44) | JAK2JAK1JAK3BRD4DHPS | |
| SCHEMBL30967777 | 0.82 | EPAS1 (0.39) | BRD4HAO1EPAS1 | |
| SCHEMBL29237705 | 0.82 | EPAS1 (0.39) | BRD4HAO1EPAS1 | |
| SCHEMBL29237404 | 0.81 | RHEB (0.38) | BRD4HAO1EPAS1 | |
| SCHEMBL30967817 | 0.81 | RHEB (0.38) | BRD4HAO1EPAS1 | |
| SCHEMBL29337732 | 0.81 | BRD4 (0.35) | JAK2JAK1JAK3BRD4HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | JAK2 125/4885JAK1 1010/4885JAK3 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.